Number of the records: 1  

The cyanobacterial metabolite nocuolin a is a natural oxadiazine that triggers apoptosis in human cancer cells.

  1. 1.
    0474362 - MBÚ 2018 RIV US eng J - Journal Article
    Voráčová, Kateřina - Hájek, Jan - Mareš, Jan - Urajová, Petra - Kuzma, Marek - Cheel Horna, José - Villunger, A. - Kapuscik, Alexandra - Bally, M. - Novák, Petr - Kabeláč, M. - Krumschnabel, G. - Lukeš, Martin - Voloshko, L. - Kopecký, Jiří - Hrouzek, Pavel
    The cyanobacterial metabolite nocuolin a is a natural oxadiazine that triggers apoptosis in human cancer cells.
    PLoS ONE. Roč. 12, č. 3 (2017), s. 1-12, č. článku e0172850. ISSN 1932-6203. E-ISSN 1932-6203
    R&D Projects: GA ČR GPP503/12/P614; GA ČR(CZ) GA14-18067S; GA MŠMT(CZ) LO1416; GA MŠMT EE2.3.30.0059
    Institutional support: RVO:61388971
    Keywords : ENZYMES * 1,3,4-OXADIAZOLE * SCAFFOLD
    OECD category: Microbiology
    Impact factor: 2.766, year: 2017

    Oxadiazines are heterocyclic compounds containing N-N-O or N-N-C-O system within a six membered ring. These structures have been up to now exclusively prepared via organic synthesis. Here, we report the discovery of a natural oxadiazine nocuolin A (NoA) that has a unique structure based on 1,2,3-oxadiazine. We have identified this compound in three independent cyanobacterial strains of genera Nostoc, Nodularia, and Anabaena and recognized the putative gene clusters for NoA biosynthesis in their genomes. Its structure was characterized using a combination of NMR, HRMS and FTIR methods. The compound was first isolated as a positive hit during screening for apoptotic inducers in crude cyanobacterial extracts. We demonstrated that NoA-induced cell death has attributes of caspase-dependent apoptosis. Moreover, NoA exhibits a potent anti-proliferative activity (0.7-4.5 micro) against several human cancer lines, with p53-mutated cell lines being even more sensitive. Since cancers bearing p53 mutations are resistant to several conventional anti-cancer drugs, NoA may offer a new scaffold for the development of drugs that have the potential to target tumor cells independent of their p53 status. As no analogous type of compound was previously described in the nature, NoA establishes a novel class of bioactive secondary metabolites.
    Permanent Link: http://hdl.handle.net/11104/0271456

     
     
Number of the records: 1  

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.